A report of a case of motor neuropathy in a patient who received the vaccine last year has led the FDA to halt its ...

After a lengthy COVID-19 surge this summer, the Bay Area is about to enter the winter respiratory virus season. Explore our ...

Factors associated with increased flare rates post-vaccination included active disease at the time, female sex, and -- most ...

Nigeria took a significant step in its fight against malaria by launching the R21 malaria vaccine on Thursday, which will be ...

Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a ...

It will become one of the first countries to roll out the new malaria vaccine, R21, after receiving a first batch of 846,200 ...

The report involved motor neuropathy in a participant of the phase 2 trial conducted outside the U.S., according to an Oct. 16 news release from the company. The participant received the vaccine in ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

Standing desks may increase the risk of swollen veins and blood clots, a study in the International Journal of Epidemiology ...

CIDRAP reports that federal health officials know of 90 cases of Oropouche virus from five states, mostly from Florida, although none of the cases is known to have been sexually transmitted. Plus: ...

Shares of Novavax NVAX lost nearly 20% on Wednesday after the company announced that the FDA has placed a clinical hold on ...

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...